Zachary R Babcock1, Stephen J Kogut2, Ami Vyas2. 1. Health Outcomes, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, RI, 02881, USA. zack.heor@gmail.com. 2. Health Outcomes, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, RI, 02881, USA.
Abstract
PURPOSE: Polypharmacy (PP) is present in many cancer survivors and may lead to lower health-related quality of life (HRQoL). The study's objective was to evaluate the association between PP and HRQoL among cancer survivors in the US. METHODS: A cross-sectional analysis of the Medical Expenditure Panel Survey (MEPS) was conducted. Our analytic sample included all adult patients with cancer, during even years 2008-2014. PP was defined as reported use of five or more unique therapeutic classes of prescription medications. The MEPS measured HRQoL using the Short Form 12-Item Health Survey Version 2 (SF-12v2) physical component summary (PCS) and mental component summary (MCS) scores. Ordinary least squares regressions were used to assess associations between PP and HRQoL controlling for demographic, socioeconomic, and clinical factors. RESULTS: PP was prevalent among 44.4% of 10.1 million cancer survivors per calendar year (on average) for years 2008, 2010, 2012, and 2014. The mean adjusted PCS score for cancer survivors with PP was 35.8 points, which was significantly lower compared with cancer survivors without PP (39.5) by 3.7 points (p value < .0001). Conversely, the mean adjusted MCS scores were not significantly lower in cancer survivors with PP compared with cancer survivors without PP (44.9 versus 45.4, p value = 0.3145). CONCLUSIONS: PP was prevalent in 44.4% of cancer survivors and was associated with significantly poorer physical HRQoL than reported in their counterparts without PP. IMPLICATIONS FOR CANCER SURVIVORS: PP should be examined closely among cancer survivors because of increased association with poorer physical HRQoL.
PURPOSE: Polypharmacy (PP) is present in many cancer survivors and may lead to lower health-related quality of life (HRQoL). The study's objective was to evaluate the association between PP and HRQoL among cancer survivors in the US. METHODS: A cross-sectional analysis of the Medical Expenditure Panel Survey (MEPS) was conducted. Our analytic sample included all adult patients with cancer, during even years 2008-2014. PP was defined as reported use of five or more unique therapeutic classes of prescription medications. The MEPS measured HRQoL using the Short Form 12-Item Health Survey Version 2 (SF-12v2) physical component summary (PCS) and mental component summary (MCS) scores. Ordinary least squares regressions were used to assess associations between PP and HRQoL controlling for demographic, socioeconomic, and clinical factors. RESULTS: PP was prevalent among 44.4% of 10.1 million cancer survivors per calendar year (on average) for years 2008, 2010, 2012, and 2014. The mean adjusted PCS score for cancer survivors with PP was 35.8 points, which was significantly lower compared with cancer survivors without PP (39.5) by 3.7 points (p value < .0001). Conversely, the mean adjusted MCS scores were not significantly lower in cancer survivors with PP compared with cancer survivors without PP (44.9 versus 45.4, p value = 0.3145). CONCLUSIONS: PP was prevalent in 44.4% of cancer survivors and was associated with significantly poorer physical HRQoL than reported in their counterparts without PP. IMPLICATIONS FOR CANCER SURVIVORS: PP should be examined closely among cancer survivors because of increased association with poorer physical HRQoL.
Entities:
Keywords:
Cancer survivors; Health-related quality of life; Medical Expenditure Panel Survey; Polypharmacy
Authors: Marwan Alrasheed; Jeff Jianfei Guo; Alex C Lin; Patricia R Wigle; Angelica Hardee; Ana L Hincapie Journal: Qual Life Res Date: 2022-01-22 Impact factor: 4.147
Authors: Celeste L Y Ewig; Yi Man Cheng; Hoi Shan Li; Jasper Chak Ling Wong; Alex Hong Yu Cho; Freddie Man Hong Poon; Chi Kong Li; Yin Ting Cheung Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244
Authors: Min-Chao Zhao; Kai Yang; Bao-Hui Yang; Shuai Guo; Ya-Ping Wang; Xiao-Wei Zhang; Hao-Peng Li Journal: J Int Med Res Date: 2021-04 Impact factor: 1.671